Cantor Fitzgerald Upgrades Immunovant (NASDAQ:IMVT) to “Strong-Buy”
Cantor Fitzgerald upgraded shares of Immunovant (NASDAQ:IMVT – Free Report) to a strong-buy rating in a research note published on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Immunovant’s FY2025 earnings at ($1.88) EPS and FY2026 earnings at ($2.92) EPS. Several other research analysts have also recently weighed in on the company. Wolfe Research […]
Cantor Fitzgerald upgraded shares of Immunovant (NASDAQ:IMVT – Free Report) to a strong-buy rating in a research note published on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Immunovant’s FY2025 earnings at ($1.88) EPS and FY2026 earnings at ($2.92) EPS. Several other research analysts have also recently weighed in on the company. Wolfe Research […]
